ARFXF News Alert Amorfix Life Science (ARFXF) 0.2739 09/27/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amorfix Life Science (ARFXF) 0.2739 $ARFXF

Amorfix announces fiscal 2014 year end results
CNW Group - Fri Jun 13, 5:00PM CDT
TSX: AMF

William Wyman appointed Amorfix Chairman of the Board
CNW Group - Thu Jun 12, 6:30AM CDT
TSX: AMF

Cervical Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpg7wz/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2013" report to their offering. 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Scope - A snapshot of the global therapeutic scenario for Cervical Cancer. - A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. Helix BioPharma Corp. Sanofi-Aventis GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd Amorfix Life Sciences Ltd. MediGene AG Nanotherapeutics, Inc. Novartis AG Chong Kun Dang Pharmaceutical Taiho Pharmaceutical Co., Ltd. Zeria Pharmaceutical Co Ltd Genmab A/S CEL-SCI Corporation Advaxis, Inc. 3SBio Inc. Dendreon Corporation Transgene SA Antigen Express, Inc. Shantha Biotechnics Limited and many more... For more information visit http://www.researchandmarkets.com/research/lp...cal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Melanoma Report - Pipeline Review
M2 - Tue Sep 03, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tjxbsj/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2013" report to their offering. 'Melanoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Melanoma. Scope - A snapshot of the global therapeutic scenario for Melanoma. - A review of the Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Melanoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. 30 of the Companies Involved in Melanoma Therapeutics Development - Johnson & Johnson - Vical Incorporated - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Viralytics Ltd. - GlaxoSmithKline plc - Nektar Therapeutics - Antigenics, Inc. - Inovio Biomedical Corporation - medac GmbH - Merck & Co., Inc. - Lentigen Corporation - Generex Biotechnology Corporation - Plexxikon Inc. - Amorfix Life Sciences Ltd. - Prolexys Pharmaceuticals, Inc. - Aposense Ltd. - Histogen, Inc. - Novartis AG - Aphios Corporation - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - SuperGen, Inc. - Teva Pharmaceutical Industries Limited - Alfacell Corporation - Bayer AG - MannKind Corporation For more information visit http://www.researchandmarkets.com/research/tjxbsj/melanoma

IIROC Trade Resumption - Amorfix Life Sciences Ltd.
Newsfile Corp - Wed Jun 05, 8:35AM CDT
Trading resumes in:

IIROC Trade Halt - Amorfix Life Sciences Ltd.
Newsfile Corp - Wed Jun 05, 8:00AM CDT
The following issues have been halted by IIROC:

Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013 Reviews Key Players Involved In the Therapeutic Development for Amyotrophic Lateral Sclerosis
M2 - Fri Apr 12, 11:28AM CDT
Research and Markets has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Amyotrophic

Amorfix announces progress on ALS program
CNW Group - Wed Mar 20, 6:00AM CDT
TSX: AMF

Amorfix announces third quarter fiscal 2013 results and financing
CNW Group - Thu Feb 14, 6:30AM CST
TSX: AMF

Pharmaceutical Executive Warren Whitehead Joins Amorfix as Chief Financial Officer
CNW Group - Thu Jan 31, 6:00AM CST
TSX: AMF

Amorfix and QPS to collaborate on Alzheimer's disease project
CNW Group - Tue Jan 29, 6:00AM CST
TSX: AMF

Amorfix to present cancer therapeutic program at AACR 2013
CNW Group - Thu Jan 24, 6:00AM CST
TSX: AMF

Amorfix provides update on ALS diagnostic program
CNW Group - Tue Jan 22, 6:00AM CST
TSX: AMF

Blood Cancer - Pipeline Review, H2 2012 Report Features Players such as Boehringer Ingelheim GmbH and Amgen Inc.
M2 - Thu Jan 17, 10:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j8jnc/blood_cancer) has announced the addition of Global Markets Direct's new report "Blood Cancer - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Blood Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Blood Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blood Cancer. Blood Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Blood Ca

Amorfix to present corporate overview at the Biotech Showcase 2013 conference
CNW Group - Fri Jan 04, 6:00AM CST
TSX: AMF




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Small Business Insurance Is a Costly Blind Spot Today

Updated Category News Views 32

A busted pipe, a fender-bender, or one bad fall can turn a promising little company into a very expensive regret. That is the plain-English value in insurance expert Michael Oehrke's overview for HelloNation: small-business insurance is not glamorous, it is not growth marketing, and it is often ignored until the owner is staring at a bill that can chew through years of...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 89

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 73

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 40

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 129

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 18

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 192

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 62

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Rescue Dog Wines Puts Holiday Bottles to Work for Dogs

Updated Category News Views 74

A Bottle With a Job Beyond the Table Holiday wine promotions usually arrive wrapped in the same tired ribbon: buy more, save a little, pour it at a party, forget it by January. Rescue Dog Wines is taking a more grounded route. The family-owned Lodi-area winery says it gives 50% of profits to animal rescue organizations, and that commitment is not being dressed up as a...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 122

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading

Top 5 Most Recently Viewed Articles

Main Street Capital Reports Impressive Q2 2025 Financials

Updated Category News Views 326

Main Street's Second Quarter 2025 Financial Performance Main Street Capital Corporation (NYSE: MAIN) recently disclosed its remarkable financial results for the second quarter of 2025. The company reported a net investment income of $88.2 million, which translates to approximately $0.99 per share. Additionally, the distributable net investment income stood at $94.3...

Continue Reading
argenx's Q1 2025 Growth: VYVGART Performance Shines Brightly

Updated Category News Views 463

Q1 2025 Financial Results Unveiled by argenx argenx SE, listed on both Nasdaq and Euronext as ARGX, is making waves in the biotech industry with its recent announcement of first-quarter financial results and a comprehensive business update. CEO Tim Van Hauwermeiren expressed enthusiasm regarding the company's trajectory, focusing on their ambitious "Vision 2030"—a...

Continue Reading
Pennsylvania's Resilient Housing Market: An Overview of Trends

Updated Category News Views 135

Pennsylvania Housing Market Shows Notable Resilience The latest data on the housing market in Pennsylvania highlights an encouraging trend, as home prices have experienced a remarkable increase of 6.5% over the past year. This consistent appreciation indicates a vigorous market, even in the face of fluctuating economic conditions. Median Home Prices Reach New Heights In...

Continue Reading
Yum China's Strategy Bolstered by Pizza Hut Buy

Updated Category News Views 129

Yum China's Bold Step Forward Here's a twist in the fast-food market worth chewing on: Yum China has wrapped up its $1.2 billion acquisition of the Pizza Hut brand in Mainland China from Yum! Brands. It's like snagging the keys to a long-coveted car after being the chauffeur for decades. Strategic Flexibility and Margin Growth What's at play? Well, Joey Wat, CEO of Yum...

Continue Reading
Insightful Overview of NCC Group plc's Recent Trading Activity

Updated Category News Views 88

Understanding Recent Trading Activities of NCC Group plc In the fast-paced world of finance, keeping an eye on trading activities can offer invaluable insights. One company that has recently been under the spotlight is NCC Group plc. The trading revelations come from public disclosures made under Rule 8.5, indicating vital movements in their securities. Key Information...

Continue Reading